Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) — ULTIMATE II

Relapsing Multiple Sclerosis (RMS) Clinical Trial

Official title:
Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Status Completed

Clinical Trial Summary

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Multiple Sclerosis
Relapsing Multiple Sclerosis (RMS)
Sclerosis

Clinical Trial Details

NCT number	NCT03277248
Study type	Interventional
Source	TG Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	August 25, 2017
Completion date	November 12, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03277261` - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )	Phase 3
Active, not recruiting	`NCT04130997` - An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis	Phase 3
Completed	`NCT02921035` - Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
Completed	`NCT04878211` - A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab	Phase 4
Recruiting	`NCT04086225` - Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	Phase 1
Completed	`NCT03745144` - Effects of Cladribine Tablets on the PK of Microgynon®	Phase 1
Active, not recruiting	`NCT04667949` - Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients	Phase 4